← Dashboard
Stock
BMY
Bristol-Myers Squibb CompanyHealth CarePharmaceuticalsLatest close $557 of 27 marquee funds currently hold2 CUSIPs mapped
Current holders
7
27 funds tracked
Ever held
16
Current + past
New this quarter
0
Exited this quarter
1
Marquee-fund ownership over time
Feb 14, 2014Nov 13, 2017Nov 16, 2020May 15, 2026
Now
8
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q2 2014 | 49Q | $35 | $55 | +55% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $45 | $55 | +22% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $45 | $55 | +22% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $45 | $55 | +22% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $45 | $55 | +22% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $45 | $55 | +22% |
| Renaissance Technologies | Q4 2024(8Q snapshot) | 6Q | $54 | $55 | +0% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Citadel Advisors 3× in & out | Q2 2025 | Q2 2026 | — | +0% |
| Scion Asset Management | Q1 2022 | Q3 2022 | → $63 | +13% |
| Berkshire Hathaway | Q4 2020 | Q2 2022 | → $65 | +25% |
| Viking Global Investors | Q4 2020 | Q2 2022 | → $65 | +25% |
| Maverick Capital 2× in & out | Q2 2019 | Q3 2021 | → $57 | +58% |
| Elliott Management | Q2 2019 | Q3 2019 | → $35 | -1% |
| JANA Partners | Q1 2017 | Q3 2017 | → $42 | +9% |
| Appaloosa | Q1 2017 | Q2 2017 | → $40 | +3% |
| Duquesne Family Office | Q1 2014 | Q2 2014 | → $35 | -3% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at BRISTOL MYERS SQUIBB CO. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
1
Filings · last 90d
23
Total on file
622
Recent SEC buffer
Most recent
Jun 5, 2026
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40002070839-26-000005Jun 5, 2026
- Form 40001975719-26-000004May 5, 2026
- Form 40001917325-26-000004Apr 2, 2026
- Form 40001451604-26-000004Apr 2, 2026
- Form 40001269070-26-000007Apr 2, 2026
- Form 40001688276-26-000006Apr 2, 2026
- Form 40001359067-26-000008Apr 2, 2026
- Form 40001418949-26-000006Apr 2, 2026
- Form 40001323134-26-000012Apr 2, 2026
- Form 40001753055-26-000006Mar 12, 2026
- Form 40002072494-26-000002Mar 12, 2026
- Form 40002080176-26-000002Mar 12, 2026
- Form 40002070839-26-000002Mar 12, 2026
- Form 40001917325-26-000002Mar 12, 2026
- Form 40001773367-26-000002Mar 12, 2026
Showing 15 of 622 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Bristol-Myers Squibb CompanyAnnual figures sourced directly from Bristol-Myers Squibb Company's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$48.19B
FY2025-0% YoY
Net income
$7.05B
FY2025+179% YoY
EPS (diluted)
$3.46
FY2025+178% YoY
Free cash flow(?)
$12.85B
FY2025-8% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for BRISTOL MYERS SQUIBB CO — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KCURRENT REPORTMay 8, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 30, 2026
- DEF 14AProxy statementMar 25, 2026
- 10-KAnnual reportFeb 11, 2026
- 8-KMaterial eventFeb 5, 2026
- 8-KCURRENT REPORTJan 12, 2026
- 8-KCURRENT REPORTNov 18, 2025
- 8-KFORM 8-KNov 10, 2025
- 8-KCURRENT REPORTNov 3, 2025
- 10-QQuarterly reportOct 30, 2025
- 8-KMaterial eventOct 30, 2025
- 10-QQuarterly reportJul 31, 2025
- 8-KMaterial eventJul 31, 2025
- 8-KCURRENT REPORTJul 25, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $60 | $57 | -4% |
| Citadel Advisors | Q2 2025 | Q2 2026 | $0.00 | — | +0% |
| Renaissance Technologies | Q4 2024 | open | $54 | $57 | +5% |
| Citadel Advisors | Q3 2024 | Q1 2025 | $0.00 | — | +0% |
| Citadel Advisors | Q3 2024 | open | $45 | $57 | +28% |
| Two Sigma Investments | Q3 2024 | open | $45 | $57 | +28% |
| D.E. Shaw | Q3 2024 | open | $45 | $57 | +28% |
| AQR Capital Management | Q3 2024 | open | $45 | $57 | +28% |
| Millennium Management | Q3 2024 | open | $45 | $57 | +28% |
| Point72 Asset Management | Q3 2024 | Q2 2025 | $45 | $44 | -2% |
| Scion Asset Management | Q1 2022 | Q3 2022 | $56 | $63 | +13% |
| Bridgewater Associates | Q2 2021 | open | $53 | $55 | +3% |
| Berkshire Hathaway | Q4 2020 | Q2 2022 | $52 | $65 | +25% |
| Viking Global Investors | Q4 2020 | Q2 2022 | $52 | $65 | +25% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $51 | $51 | +1% |
| Bridgewater Associates | Q4 2019 | Q1 2020 | $46 | $52 | +13% |
| Elliott Management | Q2 2019 | Q3 2019 | $36 | $35 | -1% |
| Maverick Capital | Q2 2019 | Q3 2021 | $36 | $57 | +58% |
| Maverick Capital | Q4 2018 | Q1 2019 | $40 | $39 | -3% |
| Bridgewater Associates | Q3 2018 | Q3 2019 | $45 | $36 | -19% |
| Bridgewater Associates | Q2 2017 | Q4 2017 | $40 | $45 | +12% |
| Appaloosa | Q1 2017 | Q2 2017 | $39 | $40 | +3% |
| JANA Partners | Q1 2017 | Q3 2017 | $39 | $42 | +9% |
| Bridgewater Associates | Q4 2015 | Q1 2017 | $45 | $37 | -16% |
| Bridgewater Associates | Q4 2014 | Q1 2015 | $40 | $41 | +2% |
| Bridgewater Associates | Q2 2014 | Q3 2014 | $35 | $33 | -5% |
| Duquesne Family Office | Q1 2014 | Q2 2014 | $36 | $35 | -3% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.